Avadel Pharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | AVDL

Avadel Pharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Avadel Pharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | AVDL

Avadel Pharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$82.4B
Takeda Pharmaceutical (TAK)$44.4B
Merck (MKKGY)$21.6B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$16.7B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.7B
Neurocrine Biosciences (NBIX)$12.4B
Catalent (CTLT)$10.7B
Madrigal Pharmaceuticals (MDGL)$7B
Orion OYJ (ORINY)$6.8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5B
Crinetics Pharmaceuticals (CRNX)$4.5B
PTC Therapeutics (PTCT)$3.1B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Soleno Therapeutics (SLNO)$2.2B
Recursion Pharmaceuticals (RXRX)$1.8B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
Ocular Therapeutix (OCUL)$1.6B
Harrow (HROW)$1.6B
NewAmsterdam Pharma (NAMS)$1.6B
Xencor (XNCR)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B